TNF receptor and steroid hormone in a combined therapy
US6225300A · kind A · utility
4Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 1998 |
| Grant date | May 1, 2001 |
| Priority date | — |
| Expiry date | Feb 27, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified treatment. In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.